The company will try to get the Komzifti QTc prolongation warning removed.
ApexOnco Front Page
Recent articles
It’s less about being fast, more about producing a better product.
Alongside full PIK3CA wild-type data, Celcuity sets the bar for gedatolisib's PIK3CA-mutant readout.
Keynote-905 finds a 50% reduction in the risk of death in (neo)adjuvant muscle-invasive bladder cancer.
But it will be up to regulators to decide if giredestrant has done enough for an all-comers label.
Enhertu improves outcomes in (neo)adjuvant breast cancer, but toxicity resurfaces.
Artios, Synnovation and Novartis show mere glimmers of activity.
Imfinzi and sasanlimab look nearly identical, but it’s a different story for Roche’s Tecentriq.
